Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis

Blood

Volumn 124, Issue 19, 2014, Pages 3007-3015

  Chakraborty, Rikhia ^a   Hampton, Oliver A ^b   Shen, Xiaoyun ^a   Simko, Stephen J ^a,b   Shih, Albert ^a   Abhyankar, Harshal ^a   Lim, Karen Phaik Har ^a,b   Covington, Kyle R ^b   Trevino, Lisa ^b   Dewal, Ninad ^b   Muzny, Donna M ^b   Doddapaneni, Harshavardhan ^b   Hu, Jianhong ^b   Wang, Linghua ^b   Lupo, Philip J ^a,b   Hicks, M John ^a,b   Bonilla, Diana L ^c   Dwyer, Karen C ^c   Berres, Marie Luise ^d   Poulikakos, Poulikos I ^d   Merad, Miriam ^d   McClain, Kenneth L ^a,b   Wheeler, David A ^b   Allen, Carl E ^a,b   Parsons, D Williams ^a,b   more..

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN; MAP2K1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1;

ARTICLE; BRAF GENE; CELL CULTURE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ERBB3 GENE; ERDHEIM CHESTER DISEASE; EXOME; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN FRAME DELETION; IN VITRO STUDY; JUVENILE XANTHOGRANULOMA; LANGERHANS CELL HISTIOCYTOSIS; MALE; MAP2K1 GENE; MISSENSE MUTATION; MOLECULAR PATHOLOGY; MUTATION RATE; PATHOGENESIS; PRESCHOOL CHILD; PROTEIN PHOSPHORYLATION; RECURRENT DISEASE; SCHOOL CHILD; SIGNAL TRANSDUCTION; SINUS HISTIOCYTOSIS; SOMATIC MUTATION; TUMOR MODEL; DENDRITIC CELL; DISEASE COURSE; GENETICS; HEK293 CELL LINE; METABOLISM;

DENDRITIC CELLS; DISEASE PROGRESSION; ERDHEIM-CHESTER DISEASE; HEK293 CELLS; HISTIOCYTOSIS, LANGERHANS-CELL; HISTIOCYTOSIS, SINUS; HUMANS; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS B-RAF; XANTHOGRANULOMA, JUVENILE;

EID: 84909609809     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-577825     Document Type: Article

References (44)

1. Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211(4):669-683.
2. Arceci RJ. The histiocytoses: the fall of the Tower of Babel. Eur J Cancer. 1999;35(5):747-767, discussion 767-769.
3. Gadner H, Minkov M, Grois N, et al; Histiocyte Society. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006-5014.
4. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919-1923.
5. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700-2703.
6. Sahm F, Capper D, Preusser M, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood. 2012;120(12):e28-e34.
7. Satoh T, Smith A, Sarde A, et al. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease [published correction appears in PLoS ONE. 2012;7(6)].
8. PLoS ONE. 2012;7(4):e33891.
9. Poulikakos PI, Solit DB. Resistance to MEK inhibitors: should we co-target upstream? Sci Signal. 2011;4(166):pe16.
10. Berres ML, Allen CE, Merad M. Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases. Adv Immunol. 2013;120:127-161.
11. Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res. 2009;33(3):355-362.
12. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
13. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458(7239):719-724.
14. Querings S, Altmüller J, Ansén S, et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS ONE. 2011;6(5):e19601.
15. Thomas RK, Nickerson E, Simons JF, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med. 2006;12(7):852-855.
16. Bainbridge MN, Wang M, Wu Y, et al. Targeted enrichment beyond the consensus coding DNA sequence exome reveals exons with higher variant densities. Genome Biol. 2011;12(7):R68.
17. Reid JG, Carroll A, Veeraraghavan N, et al. Launching genomics into the cloud: deployment of Mercury, a next generation sequence analysis pipeline. BMC Bioinformatics. 2014;15:30.
18. Allen CE, Li L, Peters TL, et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol. 2010;184(8):4557-4567.
19. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251-263.
20. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107-1120.
21. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39(suppl 1):D945-D950.
22. Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012;11(4):909-920.
23. Waterfall JJ, Arons E, Walker RL, et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2014;46(1):8-10.
24. Staudinger J, Zhou J, Burgess R, Elledge SJ, Olson EN. PICK1: a perinuclear binding protein and substrate for protein kinase C isolated by the yeast two-hybrid system. J Cell Biol. 1995;128(3):263-271.
25. Cheung LW, Hennessy BT, Li J, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011;1(2):170-185.
26. da Costa CE, Szuhai K, van Eijk R, et al. No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes Cancer. 2009;48(3):239-249.
27. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427-430.
28. Wang L, Wheeler DA. Genomic sequencing for cancer diagnosis and therapy. Annu Rev Med. 2014;65:33-48.
29. Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220-2228.
30. Nelson DS, Quispel W, Badalian-Very G, et al. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood. 2014;123(20):3152-3155.
31. Kansal R, Quintanilla-Martinez L, Datta V, Lopategui J, Garshfield G, Nathwani BN. Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis. Genes Chromosomes Cancer. 2013;52(1):99-106.
32. Bromberg-White JL, Andersen NJ, Duesbery NS. MEK genomics in development and disease. Brief Funct Genomics. 2012;11(4):300-310.
33. Nikolaev SI, Rimoldi D, Iseli C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet. 2012;44(2):133-139.
34. Rodriguez-Viciana P, Tetsu O, Tidyman WE, et al. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science. 2006;311(5765):1287-1290.
35. Schulz AL, Albrecht B, Arici C, et al. Mutation and phenotypic spectrum in patients with cardio-faciocutaneous and Costello syndrome. Clin Genet. 2008;73(1):62-70.
36. Bisogno G, Murgia A, Mammi I, Strafella MS, Carli M. Rhabdomyosarcoma in a patient with cardiofacio-cutaneous syndrome. J Pediatr Hematol Oncol. 1999;21(5):424-427.
37. Al-Rahawan MM, Chute DJ, Sol-Church K, et al. Hepatoblastoma and heart transplantation in patient with cardio-facio-cutaneous syndrome. Am J Med Genet A. 2007;143A (13): 1481-1488.
38. Makita Y, Narumi Y, Yoshida M, et al. Leukemia in Cardio-facio-cutaneous (CFC) syndrome: a patient with a germline mutation in BRAF proto-oncogene. J Pediatr Hematol Oncol. 2007;29(5):287-290.
39. Aitken SJ, Presneau N, Tirabosco R, Amary MF, O'Donnell P, Flanagan AM. An NRAS mutation in a case of Erdheim-Chester disease [published online ahead of print September 2, 2014]. Histopathology. doi:10.1111/his.12443.
40. Diamond EL, Abdel-Wahab O, Pentsova E, et al. Detection of an NRAS mutation in Erdheim-Chester disease. Blood. 2013;122(6):1089-1091.
41. Arceci RJ, Allen CE, Dunkel I, et al. Evaluation of Afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis [abstract]. Blood. 2013;122(21). Abstract 2907.
42. Jones DT, Hutter B, Jäger N, et al; International Cancer Genome Consortium PedBrain Tumor Project. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013;45(8):927-932.
43. Jaiswal BS, Kljavin NM, Stawiski EW, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 2013;23(5):603-617.
44. Lee JW, Soung YH, Kim SY, et al. Mutational analysis of the ARAF gene in human cancers. APMIS. 2005;113(1):54-57.